| Basics |
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
|
| IPO Date: |
November 9, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.41B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.03 | 2.83%
|
| Avg Daily Range (30 D): |
$0.50 | 2.81%
|
| Avg Daily Range (90 D): |
$0.55 | 2.50%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.07M |
| Avg Daily Volume (30 D): |
2.26M |
| Avg Daily Volume (90 D): |
1.73M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
77 |
| Avg Trade Size (Sh.) (90 D): |
75 |
| Institutional Trades |
| Total Inst.Trades: |
7,411 |
| Avg Inst. Trade: |
$3.31M |
| Avg Inst. Trade (30 D): |
$4.22M |
| Avg Inst. Trade (90 D): |
$4.98M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.22M |
| Avg Closing Trade (30 D): |
$9.18M |
| Avg Closing Trade (90 D): |
$10.04M |
| Avg Closing Volume: |
175.3K |
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-.74
|
$-.29
|
$-1.6
|
|
Diluted EPS
|
$-.74
|
$-.29
|
$-1.6
|
|
Revenue
|
$ 166.8M
|
$ 212.53M
|
$ 781.37M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -92.23M
|
$ -36.35M
|
$ -197.88M
|
|
Operating Income / Loss
|
$ -83.33M
|
$ -26.16M
|
$ -164.98M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -52.79M
|
$ 14.38M
|
$ 60.31M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Mar 19, 2004:
1:200
|
|
|
|
